Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers

Purpose: The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children with severe combined immunodeficiency (SCID) in a prospective natural history study of hematopoietic stem cell transplant (HSCT) outcomes over the last decade. Despite newborn screening (NBS) for SCID, infections occurred prior to HSCT. This study's objectives were to define the types and timing of infection prior to HSCT in patients diagnosed via NBS or by family history (FH) and to understand the breadth of strategies employed at PIDTC centers for infection prevention.

Methods: We analyzed retrospective data on infections and pre-transplant management in patients with SCID diagnosed by NBS and/or FH and treated with HSCT between 2010 and 2014. PIDTC centers were surveyed in 2018 to understand their practices and protocols for pre-HSCT management.

Results: Infections were more common in patients diagnosed via NBS (55%) versus those diagnosed via FH (19%) (p = 0.012). Outpatient versus inpatient management did not impact infections (47% vs 35%, respectively; p = 0.423). There was no consensus among PIDTC survey respondents as to the best setting (inpatient vs outpatient) for pre-HSCT management. While isolation practices varied, immunoglobulin replacement and antimicrobial prophylaxis were more uniformly implemented.

Conclusion: Infants with SCID diagnosed due to FH had lower rates of infection and proceeded to HSCT more quickly than did those diagnosed via NBS. Pre-HSCT management practices were highly variable between centers, although uses of prophylaxis and immunoglobulin support were more consistent. This study demonstrates a critical need for development of evidence-based guidelines for the pre-HSCT management of infants with SCID following an abnormal NBS.

Trial Registration: NCT01186913.

Citing Articles

Parental Engagement in Identifying Information Needs After Newborn Screening for Families of Infants with Suspected Athymia.

Howley E, Soomann M, Kreins A J Clin Immunol. 2024; 44(3):79.

PMID: 38457046 PMC: 10923976. DOI: 10.1007/s10875-024-01678-w.

Reducing Mortality and Morbidity in Children with Severe Combined Immunodeficiency in Switzerland: the Role of Newborn Screening.

Soomann M, Prader S, Pinto Monteiro A, Zeilhofer U, Hauri-Hohl M, Gungor T J Clin Immunol. 2024; 44(1):39.

PMID: 38165471 PMC: 10761526. DOI: 10.1007/s10875-023-01640-2.

Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.

Eissa H, Thakar M, Shah A, Logan B, Griffith L, Dong H J Allergy Clin Immunol. 2023; 153(1):287-296.

PMID: 37793572 PMC: 11294800. DOI: 10.1016/j.jaci.2023.09.027.

Progress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity.

Arnold D, Pai S Curr Opin Pediatr. 2023; 35(6):663-670.

PMID: 37732933 PMC: 10872717. DOI: 10.1097/MOP.0000000000001292.

Impact of newborn screening for SCID on the management of congenital athymia.

Howley E, Golwala Z, Buckland M, Barzaghi F, Ghosh S, Hackett S J Allergy Clin Immunol. 2023; 153(1):330-334.

PMID: 37678573 PMC: 10940165. DOI: 10.1016/j.jaci.2023.08.031.

References

Atkinson C, Walter S, Sharland M, Tookey P, Luck S, Peckham C . Use of stored dried blood spots for retrospective diagnosis of congenital CMV. J Med Virol. 2009; 81(8):1394-8. DOI: 10.1002/jmv.21543. View

Haddad E, Logan B, Griffith L, Buckley R, Parrott R, Prockop S . SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018; 132(17):1737-1749. PMC: 6202916. DOI: 10.1182/blood-2018-03-840702. View

Dorsey M, Dvorak C, Cowan M, Puck J . Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. J Allergy Clin Immunol. 2017; 139(3):733-742. PMC: 5385855. DOI: 10.1016/j.jaci.2017.01.005. View

Griffith L, Cowan M, Kohn D, Notarangelo L, Puck J, Schultz K . Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol. 2008; 122(6):1087-96. PMC: 3357108. DOI: 10.1016/j.jaci.2008.09.045. View

Dergousoff B, Vayalumkal J, Wright N . Survey of Infection Control Precautions for Patients with Severe Combined Immune Deficiency. J Clin Immunol. 2019; 39(8):753-761. DOI: 10.1007/s10875-019-00671-y. View

Dvorak C, Cowan M, Logan B, Notarangelo L, Griffith L, Puck J . The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013; 33(7):1156-64. PMC: 3784642. DOI: 10.1007/s10875-013-9917-y. View

Dvorak C, Puck J, Wahlstrom J, Dorsey M, Melton A, Cowan M . Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. Blood Adv. 2018; 1(20):1694-1698. PMC: 5728344. DOI: 10.1182/bloodadvances.2017010835. View

Griffith L, Cowan M, Notarangelo L, Puck J, Buckley R, Candotti F . Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009; 124(6):1152-60.e12. PMC: 2831471. DOI: 10.1016/j.jaci.2009.10.022. View

Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies E . Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood. 2011; 117(11):3243-6. DOI: 10.1182/blood-2010-08-300384. View

10.

Gaspar H, Qasim W, Davies E, Rao K, Amrolia P, Veys P . How I treat severe combined immunodeficiency. Blood. 2013; 122(23):3749-58. DOI: 10.1182/blood-2013-02-380105. View

11.

Kelty W, Beatty S, Wu S, Hanson I, Demmler-Harrison G, Martinez C . The role of breast-feeding in cytomegalovirus transmission and hematopoietic stem cell transplant outcomes in infants with severe combined immunodeficiency. J Allergy Clin Immunol Pract. 2019; 7(8):2863-2865.e3. DOI: 10.1016/j.jaip.2019.05.041. View

12.

Kwan A, Church J, Cowan M, Agarwal R, Kapoor N, Kohn D . Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013; 132(1):140-50. PMC: 3759317. DOI: 10.1016/j.jaci.2013.04.024. View

13.

Verbsky J, Thakar M, Routes J . The Wisconsin approach to newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2012; 129(3):622-7. DOI: 10.1016/j.jaci.2011.12.004. View

14.

Amatuni G, Currier R, Church J, Bishop T, Grimbacher E, Nguyen A . Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017. Pediatrics. 2019; 143(2). PMC: 6361357. DOI: 10.1542/peds.2018-2300. View

15.

Kimberlin D, Jester P, Sanchez P, Ahmed A, Arav-Boger R, Michaels M . Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015; 372(10):933-43. PMC: 4401811. DOI: 10.1056/NEJMoa1404599. View

16.

Lanzieri T, Dollard S, Josephson C, Schmid D, Bialek S . Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. Pediatrics. 2013; 131(6):e1937-45. PMC: 4850548. DOI: 10.1542/peds.2013-0076. View

17.

Shearer W, Dunn E, Notarangelo L, Dvorak C, Puck J, Logan B . Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2013; 133(4):1092-8. PMC: 3972266. DOI: 10.1016/j.jaci.2013.09.044. View

18.

Whitley R . The use of antiviral drugs during the neonatal period. Clin Perinatol. 2012; 39(1):69-81. PMC: 3290126. DOI: 10.1016/j.clp.2011.12.004. View

19.

Pai S, Logan B, Griffith L, Buckley R, Parrott R, Dvorak C . Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014; 371(5):434-46. PMC: 4183064. DOI: 10.1056/NEJMoa1401177. View

20.

Heimall J, Logan B, Cowan M, Notarangelo L, Griffith L, Puck J . Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017; 130(25):2718-2727. PMC: 5746165. DOI: 10.1182/blood-2017-05-781849. View